Nicotinamide phosphoribosyltransferase (NAMPT) functions as the rate-limiting step in the nicotinamide adenine dinucleotide (NAD+) salvage pathway. Simple fact: this enzyme sustains NAD+ pools critical for cellular energetics. The review team noted that maintenance of NAD+ underpins the activity of multiple NAD+-dependent enzymes — sirtuins, PARPs, and CD38 among them — and thereby links metabolism to DNA repair and stress responses. The authors emphasized a dual existence for NAMPT. Intracellular iNAMPT drives cellular NAD+ synthesis, while extracellular eNAMPT has been proposed to participate in interorgan communication and inflammatory signaling, although the precise extracellular mechanisms require further mechanistic definition in the literature cited.
Data in the review covered NAD+ biosynthetic pathways and stressed subcellular compartmentalization as a determinant of functional outcomes. NAD+ levels and pathway flux vary by compartment, and the authors discussed circadian regulation as an additional layer controlling NAMPT expression and NAD+ availability. They also described NAPRT-mediated metabolic bypass — a route that can reduce reliance on NAMPT-driven salvage by permitting alternative precursor use — meaning that simple measurements of NAMPT expression do not reliably predict NAD+ pathway dependence in tissues or tumors.
The review cataloged physiological and pathological roles of the NAMPT–NAD+ axis across multiple systems. Reduced NAMPT activity and consequent NAD+ depletion were associated with metabolic dysfunction, tissue injury, and increased neuronal vulnerability in degenerative settings. By contrast, elevated NAMPT activity correlated with enhanced metabolic fitness in tumors and amplified inflammatory responses in certain disease contexts. The cohort of evidence presented by the authors supports a context-dependent model: NAMPT alterations can be detrimental or adaptive depending on organ, disease stage, NAD+ consumption rates, and precursor availability.
Cancer biology received focused attention. The authors reported that increased NAMPT activity can support tumor metabolic demands and thereby promote tumor fitness. Because of that relationship, NAMPT inhibitors have been explored as anticancer agents. The review described ongoing preclinical and early clinical interest in NAMPT inhibition, while cautioning that NAMPT expression alone is an imperfect biomarker of tumor NAD+ dependence. Tumor heterogeneity and alternative NAD+ synthesis pathways (for example, NAPRT-mediated routes) complicate straightforward prediction of which malignancies will respond to NAMPT-directed therapy.
Clinical translation of NAMPT-targeted strategies, the authors reported, faces several limitations. Systemic NAD+ depletion is a fundamental risk when blocking a major biosynthetic enzyme. Observed adverse effects that limit development include hematological and gastrointestinal toxicity. The review also noted pharmacokinetic constraints of existing inhibitors and emphasized tumor heterogeneity as a biological barrier to consistent therapeutic responses. These factors together restrict the broad application of NAMPT inhibitors without refined patient selection and delivery methods.
The review evaluated therapeutic alternatives beyond direct inhibition. Investigators described the potential utility of NAD+ precursors, NAMPT activation, and indirect modulators in selected degenerative and metabolic disorders. For oncology, NAMPT inhibitors remain under investigation but their development will likely require tissue-selective delivery, close pharmacodynamic monitoring, and predictive biomarkers to identify susceptible patient subgroups. The authors made clear that NAMPT expression alone is insufficient as a stratification tool; composite biomarker strategies that account for NAD+ consumption, precursor availability, and alternative biosynthetic enzyme expression will be needed.
The review concluded with practical translational imperatives identified by the authors. They called for methods enabling tissue-selective modulation of NAMPT activity, direct pharmacodynamic readouts of NAD+ pathway engagement, and biomarker-guided patient stratification in clinical trials. The authors also highlighted the need to overcome systemic toxicity and pharmacokinetic issues observed with current inhibitors. Specific dosing regimens, clinical trial endpoints, and patient selection criteria were not detailed in the abstract; the source did not report those trial-level specifics in the provided summary. The review underscores that further mechanistic clarity and biomarker development are prerequisites before broad clinical application of NAMPT-directed therapies.